Lazard Asset Management Portfolio holdings
AUM
$72.7B
1-Year Return
14.89%
This Quarter Return
+11.1%
1 Year Return
+14.89%
3 Year Return
+61.14%
5 Year Return
+112.7%
10 Year Return
+262.42%
AUM
$79B
AUM Growth
+$5.52B
(+7.5%)
Cap. Flow
-$7.71B
Cap. Flow
% of AUM
-9.75%
Top 10 Holdings %
Top 10 Hldgs %
24.46%
Holding
2,612
New
284
Increased
737
Reduced
832
Closed
260
Top Buys
| 1 |
Chubb
CB
|
+$574M |
| 2 |
American Electric Power
AEP
|
+$284M |
| 3 |
Ulta Beauty
ULTA
|
+$187M |
| 4 |
CVS Health
CVS
|
+$177M |
| 5 |
McDonald's
MCD
|
+$151M |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
+$422M |
| 2 |
Johnson & Johnson
JNJ
|
+$213M |
| 3 |
Aon
AON
|
+$192M |
| 4 |
Norfolk Southern
NSC
|
+$183M |
| 5 |
CyberArk
CYBR
|
+$168M |
Sector Composition
| 1 | Technology | 20.99% |
| 2 | Financials | 14.11% |
| 3 | Healthcare | 13.38% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 9.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1901
Biohaven
BHVN
$1.48B
| $12K | ﹤0.01% |
283
+3
| +1% | +$127 |
|
1902
LPL Financial
LPLA
$27.4B
| $12K | ﹤0.01% |
54
-230
| -81% | -$51.1K |
|
1903
Renovaro
RENB
$47.4M
| $12K | ﹤0.01% |
+3,892
| New | +$12K |
|
1904
Rentokil
RTO
$12.8B
| $12K | ﹤0.01% |
452
+240
| +113% | +$6.37K |
|
1905
Weis Markets
WMK
$1.73B
| $12K | ﹤0.01% |
191
-1,996
| -91% | -$125K |
|
1906
Invesco
IVZ
$9.88B
| $11K | ﹤0.01% |
668
+134
| +25% | +$2.21K |
|
1907
ProQR Therapeutics
PRQR
$235M
| $11K | ﹤0.01% |
5,860
-354
| -6% | -$665 |
|
1908
Scilex Holding
SCLX
$176M
| $11K | ﹤0.01% |
162
| – | – |
|
1909
Vanda Pharmaceuticals
VNDA
$264M
| $11K | ﹤0.01% |
2,637
-9,047
| -77% | -$37.7K |
|
1910
CBRE Group
CBRE
$48.4B
| $10K | ﹤0.01% |
110
-25,920
| -100% | -$2.36M |
|
1911
MarineMax
HZO
$545M
| $10K | ﹤0.01% |
270
+62
| +30% | +$2.3K |
|
1912
Lineage Cell Therapeutics
LCTX
$279M
| $10K | ﹤0.01% |
9,415
+578
| +7% | +$614 |
|
1913
Qorvo
QRVO
$8.26B
| $10K | ﹤0.01% |
89
+14
| +19% | +$1.57K |
|
1914
Repligen
RGEN
$6.77B
| $10K | ﹤0.01% |
66
-2
| -3% | -$303 |
|
|
BLUE
1915
DELISTED
bluebird bio
BLUE
| $9K | ﹤0.01% |
343
-20
| -6% | -$525 |
|
1916
Conagra Brands
CAG
$9.28B
| $9K | ﹤0.01% |
325
| – | – |
|
1917
iShares Core MSCI Europe ETF
IEUR
$6.87B
| $9K | ﹤0.01% |
167
-3,033
| -95% | -$163K |
|
1918
Jasper Therapeutics
JSPR
$41.9M
| $8K | ﹤0.01% |
1,150
+36
| +3% | +$250 |
|
1919
ResMed
RMD
$39.6B
| $8K | ﹤0.01% |
52
+1
| +2% | +$154 |
|
1920
Adverum Biotechnologies
ADVM
$69M
| $7K | ﹤0.01% |
993
-56
| -5% | -$395 |
|
1921
Euroseas
ESEA
$432M
| $7K | ﹤0.01% |
+299
| New | +$7K |
|
1922
Fresenius Medical Care
FMS
$14.6B
| $7K | ﹤0.01% |
357
-314
| -47% | -$6.16K |
|
1923
Orion
OEC
$570M
| $7K | ﹤0.01% |
257
-1,384
| -84% | -$37.7K |
|
1924
Cartesian Therapeutics
RNAC
$255M
| $7K | ﹤0.01% |
371
-21
| -5% | -$396 |
|
|
LENZ
1925
LENZ Therapeutics
LENZ
$1.19B
| $7K | ﹤0.01% |
410
-24
| -6% | -$410 |
|